Bausch Health up 3% premarket on raised guidance

|About: Bausch Health Companies Inc. (BHC)|By:, SA News Editor

Bausch Health Companies (BHC) Q2 results: Revenues: $2,152M (+1.1%); Product sales: $2,122M (+1.0%); Other revenues: $30M (7.1%).

Segment Sales: Bausch + Lomb/International: $1,208M (-0.1%); Salix: $509M (+15%); Ortho Dermatologics: $122M (-13%); Diversified Products: $313M (-7%).

Net Loss: ($171M) (+80.4%); Loss Per Share: ($0.49) (+80.3%); Non-GAAP Net Income: $372M (+13.8%); Non-GAAP EPS: $1.04; CF Ops: $339M (+52.7%).

2019 Guidance: Revenues: $8.40B - 8.60B from $8.35B - 8.55B; non-GAAP EBITDA: $3.425B - 3.575B from $3.40B - 3.55B.

Shares are up 3% premarket.

Previously: Bausch Health Companies EPS misses by $0.02, revenue in-line (Aug. 6)

Subscribe for full text news in your inbox